PROK Stock Chart & Stats
$27.50
$0.00(0.00%)
At close: 4:00 PM EDT
$27.50
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$25.51 - $63.35
Previous CloseN/A
Volume0.00
Average Volume (3M)5.34K
Market Cap
$8.06B
Enterprise Value$1.32K
Total Cash (Recent Filing)$224.94M
Total Debt (Recent Filing)$3.78M
Price to Earnings (P/E)―
Beta-4.00
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding205,199,700
10 Day Avg. Volume9,774
30 Day Avg. Volume5,345
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)-0.30
Price to Sales (P/S)335.98
P/FCF Ratio-2.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$99.12Price Target Upside260.43% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-11.24
Revenue Forecast (FY)$8.92M
Bulls Say, Bears Say
Bulls Say
Regulatory Alignment (eGFR Surrogate)FDA confirmation that eGFR slope can serve as a surrogate endpoint creates a durable regulatory pathway for accelerated approval. This materially reduces regulatory uncertainty for the Phase 3 program, shortens potential time-to-market if topline is positive, and strengthens the program's strategic appeal to partners and payers over the next several quarters.
Phase 3 Enrollment On TrackOn-track enrollment for PROACT 1 lowers execution risk versus delayed recruitment and supports the planned pivotal timeline. A statistically powered, ongoing Phase 3 with an expected 2027 topline readout preserves the value of the clinical program and keeps approval and partnering timelines intact across the 2–6 month horizon and beyond.
Cash Runway Into Mid-2027Substantial cash and securities give the company a clear runway to complete pivotal activities through the anticipated topline readout. This liquidity materially reduces near-term financing pressure, allowing focus on trial execution and regulatory interaction rather than urgent capital raises, which supports program continuity over the medium term.
Bears Say
High Cash BurnSustained negative operating and free cash flow at this scale means the company will remain dependent on existing cash and potential external financing to complete development. If trial costs or timelines extend, the burn rate could force dilution or restrictive deals, creating persistent funding risk that affects strategic flexibility for months to come.
Minimal And Declining RevenueVery low and shrinking revenue underscores the pre-commercial nature of the business and dependence on a single lead asset for future monetization. Without diversified income streams, the company’s long-term viability rests on clinical and regulatory success, increasing operational risk and reliance on capital markets or partnerships.
Balance-sheet Volatility & Asset DeclineLarge swings in shareholders' equity and a marked decline in total assets suggest past capital raises, remeasurements, or write-downs, which increase uncertainty about capital structure. This structural volatility can lead to investor concern, potential dilution, and reduced financial flexibility if further funding is needed before commercialization.
ProKidney News
PROK FAQ
What was Prokidney Corp.’s price range in the past 12 months?
Prokidney Corp. lowest stock price was $25.51 and its highest was $63.35 in the past 12 months.
What is Prokidney Corp.’s market cap?
Prokidney Corp.’s market cap is $8.06B.
When is Prokidney Corp.’s upcoming earnings report date?
Prokidney Corp.’s upcoming earnings report date is Nov 16, 2026 which is in 101 days.
How were Prokidney Corp.’s earnings last quarter?
Currently, no data Available
Is Prokidney Corp. overvalued?
According to Wall Street analysts Prokidney Corp.’s price is currently Undervalued.
Does Prokidney Corp. pay dividends?
Prokidney Corp. does not currently pay dividends.
What is Prokidney Corp.’s EPS estimate?
Prokidney Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prokidney Corp. have?
Prokidney Corp. has 205,199,700 shares outstanding.
What happened to Prokidney Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Prokidney Corp.?
Currently, no hedge funds are holding shares in MX:PROK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProKidney Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$99.12 (260.43% Upside)
$99.12 (260.43% Upside)
Blogger Sentiment
Bullish
MX:PROK Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.90%
Trailing 12-Months
Company Description
Prokidney Corp.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
PROK Stock 12 Month Forecast
Average Price Target
$99.12
▲(260.43% Upside)